Status
Conditions
Treatments
About
The main research question of this patient survey is to assess AF patients' preferences associated with different attributes which describe the different available anticoagulation treatment options (VKA or NOACs and, in case of NOACs, Apixaban, Dabigatran or Rivaroxaban).
VKA (Waran®) will be compared to Rivaroxaban.
Full description
The objective of this study is to investigate the following research questions in a cross-sectional survey of Swedish AF patients being treated either with a VKA or with a NOAC:
Which attributes of a medication to prevent stroke do AF patients view as important? Do AF patients have a preference regarding the attributes of the medication options VKA or NOAC and, in case of NOACs, with regards to rivaroxaban attributes? Are there subgroups of AF patients whose preference for one of the medication options appears above or below average? What is the quality of life of Swedish AF patients? Are there subgroups with differences in their quality of life (for example: subgroups of patients with different CHA2DS2-VASc scores)? Which burden do Swedish AF patients experience in association with their anticoagulation therapy? Are there differences in the burden of treatment (ACTS) between patients treated with VKA or with NOACs?
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion criteria for AF patients in both the NOAC and the VKA groups:
Additional inclusion criterion for Group 1 (NOAC):
Additional inclusion criterion for Group 2 (VKA):
Exclusion criteria
Exclusion criteria for both groups:
382 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal